Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | PDE2A | O00408 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27469976 | 0.86 | KDM1A (0.48) | KDM1AMAOAMAOBNPC1RAB9A | |
| SCHEMBL10254379 | 0.84 | KDM1A (0.49) | KDM1AMAOAMAOBNPC1RAB9A | |
| SCHEMBL14303885 | 0.82 | HRH3 (0.47) | KDM1AMAOAMAOBNPC1RAB9A | |
| SCHEMBL30471983 | 0.82 | KDM1A (0.48) | KDM1AMAOAMAOBNPC1RAB9A | |
| SCHEMBL10288360 | 0.82 | KDM1A (0.48) | KDM1AMAOAMAOBNPC1RAB9A | |
| SCHEMBL11951542 | 0.82 | KMT2A (0.50) | KDM1AMAOAMAOBNPC1RAB9A | |
| SCHEMBL8690482 | 0.81 | KDM1A (0.50) | KDM1AMAOAMAOBNPC1RAB9A | |
| SCHEMBL13167406 | 0.81 | KDM1A (0.47) | KDM1AMAOAMAOBNPC1RAB9A | |
| SCHEMBL27469891 | 0.81 | KDM1A (0.47) | KDM1AMAOAMAOBNPC1RAB9A | |
| SCHEMBL24258303 | 0.80 | KDM1A (0.46) | KDM1AMAOAMAOBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382296-A1 | NITROGEN-CONTAINING FUSED THREE RING PRMT5 INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO LTD (CN) | 2025-12-18 | — | — | US | disclosed |
| EP-4251624-B1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4567036-A1 | NITROGEN-CONTAINING FUSED THREE RING PRMT5 INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| WO-2025098450-A1 | PRMT5 INHIBITOR AND PREPARATION METHOD THEREFOR | 北京泰德制药股份有限公司 | 2025-05-15 | — | — | WO | disclosed |
| US-20240101570-A1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC. | 2024-03-28 | — | — | US | disclosed |
| WO-2022115377-A1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2021136238-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | 武汉朗来科技发展有限公司 | 2021-07-08 | — | — | WO | disclosed |
| EP-3760625-A1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | F. Hoffmann-La Roche AG (CH) | 2021-01-06 | — | — | EP | disclosed |
| WO-2017004500-A9 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| WO-2012006004-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-12 | — | — | WO | disclosed |
| US-7795457-B2 | antitumor agents; anticancer agents; structurally related to the leptomycin family; Leptolstatin | KOSAN BIOSCIENCES INCORPORATED (US) | 2010-09-14 | — | — | US | disclosed |
| US-20080214617-A1 | Carbamate compounds | KOSAN BIOSCIENCES INCORPORATED | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382296-A1 | NITROGEN-CONTAINING FUSED THREE RING PRMT5 INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | PRMT5, PRMT1, PRMT8 | KDM1A 164/4885MAOA 4192/4885MAOB 3998/4885 |
| US-20170190729-A1 | POLYENE MACROLIDE DERIVATIVE | ERG28, RPL23, RPL10 | KDM1A 3551/4885MAOA 2448/4885MAOB 645/4885 |
| US-20240101570-A1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | KDM1A 37/4885MAOA 3279/4885MAOB 3113/4885 |
| US-20080214617-A1 | Carbamate compounds | CPS1, RB1, PRMT1 | KDM1A 56/4885MAOA 4699/4885MAOB 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.